Near-thorough QT study as part of a first-in-man study

Journal of Clinical Pharmacology

Volumn 48, Issue 10, 2008, Pages 1146-1157

  Malik, Marek ^a   Hnatkova, Katerina ^a   Ford, John ^b   Madge, David ^b  

^a St Paul's Cardiac Electrophysiology   (United Kingdom)

^b Xention Limited   (United Kingdom)

Author keywords

Electrocardiography; First in man study; QT interval

Indexed keywords

PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; FIRST IN MAN STUDY; HEART RATE VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; QT INTERVAL; QT PROLONGATION; RR INTERVAL; STUDY;

ADULT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TIME FACTORS; YOUNG ADULT;

EID: 51849093126     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008323261     Document Type: Article

References (25)

1. ICH E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: guidance to industry. Fed Regist. 2005 ; 70: 61134-61135.
2. Natekar M., Mahajan V., Satra A., O'Kelly M., Karnad DR Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies. Clin Pharmacol Ther. 2008 ; 83: 489-491.
3. Stockbridge N., Brown BD Annotated ECG waveform data at FDA. J Electrocardiol. 2004 ; 37 (suppl): 63-64.
4. Malik M. Detection of drug-induced proarrhythmia: balancing preclinical and clinical studies. Heart Rhythm. 2005 ; 2: 773-776.
5. London MJ Validation testing of the SEER real-time digital Holter monitor. J Cardiothorac Vasc Anesth. 1996 ; 10: 497-501.
6. Batchvarov V., Hnatkova K., Malik M. Assessment of noise in digital electrocardiograms. Pacing Clin Electrophysiol. 2002 ; 25: 499-503.
7. Daskalov IK, Dotsinsky IA, Christov II Developments in ECG acquisition, preprocessing, parameter measurement, and recording. IEEE Eng Med Biol. 1998 ; 17: 50-58.
8. Meyer CR, Keiser HN Electrocardiogram baseline noise estimation and removal using cubic splines and state-space computation techniques. Comput Biomed Res. 1977 ; 10: 459-470.
9. Malik M., Färbom P., Batchvarov V., Hnatkova K., Camm AJ Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002 ; 87: 220-228.
10. Batchvarov VN, Ghuran A., Smetana P., et al. QT-RR relationship in healthy subjects exhibits substantial inter-subject variability and high intra-subject stability. Am J Physiol Heart Circ Physiol. 2002 ; 282: H2356 - H2363.
11. Garnett CE, Beasley N., Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008 ; 48: 13-18.
12. Fridericia LS Die Systolendauer im Elekrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand. 1920 ; 53: 469-486.
13. Malik M. The impression in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol. 2002 ; 25: 209-216.
14. Malik M., Andreas J-O., Hnatkova K., et al. Thorough QT/QTc study in patients with advanced Parkinson's disease-cardiac safety of rotigotine. Clin Pharmacol Ther. In press.
15. Sarapa N., Nickens DJ, Raber SR, Reynolds RR, Amantea MA Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther. 2008 ; 83: 153-159.
16. Kubitza D., Mueck W., Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf. 2008 ; 31: 67-77.
17. Malhotra BK, Glue P., Sweeney K., Anziano R., Mancuso J., Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007 ; 81: 377-385.
18. Hulhoven R., Rosillon D., Letiexhe M., Meeus MA, Daoust A., Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007 ; 63: 1011-1017.
19. Malik M., Hnatkova K., Batchvarov V., Gang Y., Smetana P., Camm AJ Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol. 2004 ; 27: 1659-1669.
20. Zhang J., Machado SG Statistical issues including design and sample size calculation in thorough QT/QTc studies. J Biopharm Stat. 2008 ; 18: 451-467.
21. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability-standards of measurement, physiological interpretation, and clinical use. Circulation. 1996 ; 93: 1043-1065.
22. Berntson GG, Bigger JT Jr, Eckberg DL, et al. Heart rate variability: origins, methods, and interpretative caveats. Psychophysiology. 1997 ; 34: 623-648.
23. Azie NE, Adams G., Darpo B., et al. Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies. Ann Noninvasive Electrocardiol. 2004 ; 9: 166-174.
24. Darpo B., Agin M., Kazierad DJ, et al. Man versus machine: is there an optimal method for QT measurements in thorough QT studies ? J Clin Pharmacol. 2006 ; 46: 598-612.
25. Malik M., Hnatkova K., Smetana P., Schmidt A. Accurately measured and heart-rate corrected QTc intervals do not show any daytime variability [abstract]. Eur Heart J. 2007 ; 28: 624.